243 related articles for article (PubMed ID: 31412230)
1. MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS.
Malik N; Nikitski AV; Klam E; Hunt J; Witt B; Chadwick B; Nikiforov YE; Abraham D
Endocr Pract; 2019 Dec; 25(12):1255-1262. PubMed ID: 31412230
[No Abstract] [Full Text] [Related]
2. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
4. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
5. Effect of BRAF
Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
[TBL] [Abstract][Full Text] [Related]
6. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
[TBL] [Abstract][Full Text] [Related]
7. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer.
Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518
[TBL] [Abstract][Full Text] [Related]
8. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
9. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
10. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
11. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
13. A six-genotype genetic prognostic model for papillary thyroid cancer.
Shen X; Liu R; Xing M
Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244
[TBL] [Abstract][Full Text] [Related]
14. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
15. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
16. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
18. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
19. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
20. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]